Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
- Resource Type
- Authors
- Xiyue Yan; Yaping Zhang; Pan Hu; Wenyu Shi; Hong Zhou
- Source
- OncoTargets and Therapy. 13:4877-4892
- Subject
- 0301 basic medicine
Chronic lymphocytic leukemia
Drug resistance
Pathogenesis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Acquired resistance
immune system diseases
hemic and lymphatic diseases
Medicine
Bruton's tyrosine kinase
Pharmacology (medical)
biology
business.industry
breakpoint cluster region
medicine.disease
030104 developmental biology
Oncology
chemistry
030220 oncology & carcinogenesis
Ibrutinib
Cancer research
biology.protein
business
Tyrosine kinase
- Language
- ISSN
- 1178-6930
Bruton's tyrosine kinase (BTK), a pivotal component of B-cell receptor (BCR) signaling, has been recognized as an important driver of the pathogenesis of chronic lymphocytic leukemia. Ibrutinib is a highly active and selectively irreversible inhibitor of BTK, which has been approved to be effective in both frontline and recurrent therapy of CLL. Acquired resistance has become a greater problem than initially anticipated with the widespread use of ibrutinib. An ongoing exploration of the mechanisms of ibrutinib resistance (IR) in CLL has revealed potentially useful therapeutic targets. New drugs expected to overcome IR in CLL are in the early stages of clinical development. This study aimed to summarize the possible mechanisms of IR and retrospectively analyze promising therapies that might have superior efficacy in overcoming IR.